XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   26,335,418      
Beginning balance at Dec. 31, 2021 $ 127,115 $ 3 $ 324,237 $ (252) $ (196,873)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (20,808)       (20,808)
Stock-based compensation 2,069   2,069    
Foreign exchange translation adjustment (58)     (58)  
Shares issued in connection with the Company's stock option plan (in shares)   852      
Shares issued in connection with the Company's stock option plan 5   5    
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)   2,904,113      
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs 29,638   29,638    
Ending balance (in shares) at Mar. 31, 2022   29,240,383      
Ending balance at Mar. 31, 2022 137,961 $ 3 355,949 (310) (217,681)
Beginning balance (in shares) at Dec. 31, 2021   26,335,418      
Beginning balance at Dec. 31, 2021 127,115 $ 3 324,237 (252) (196,873)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (63,933)        
Ending balance (in shares) at Sep. 30, 2022   30,564,995      
Ending balance at Sep. 30, 2022 108,810 $ 3 369,999 (386) (260,806)
Beginning balance (in shares) at Mar. 31, 2022   29,240,383      
Beginning balance at Mar. 31, 2022 137,961 $ 3 355,949 (310) (217,681)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (21,901)       (21,901)
Stock-based compensation 2,062   2,062    
Foreign exchange translation adjustment (350)     (350)  
Shares issued in connection with the Company's Employee stock purchase plan (in shares)   24,612      
Shares issued in connection with the Company's Employee stock purchase plan 130   130    
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)   1,300,000      
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs 9,946   9,946    
Ending balance (in shares) at Jun. 30, 2022   30,564,995      
Ending balance at Jun. 30, 2022 127,848 $ 3 368,087 (660) (239,582)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (21,224)       (21,224)
Stock-based compensation 1,912   1,912    
Foreign exchange translation adjustment 274     274  
Ending balance (in shares) at Sep. 30, 2022   30,564,995      
Ending balance at Sep. 30, 2022 $ 108,810 $ 3 369,999 (386) (260,806)
Beginning balance (in shares) at Dec. 31, 2022 39,307,286 39,307,286      
Beginning balance at Dec. 31, 2022 $ 113,684 $ 4 427,925 3,035 (317,280)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (25,272)       (25,272)
Stock-based compensation 1,979   1,979    
Foreign exchange translation adjustment 776     776  
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)   5,096,552      
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs 51   51    
Ending balance (in shares) at Mar. 31, 2023   44,403,838      
Ending balance at Mar. 31, 2023 $ 91,218 $ 4 429,955 3,811 (342,552)
Beginning balance (in shares) at Dec. 31, 2022 39,307,286 39,307,286      
Beginning balance at Dec. 31, 2022 $ 113,684 $ 4 427,925 3,035 (317,280)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ (72,040)        
Ending balance (in shares) at Sep. 30, 2023 44,595,383 44,595,383      
Ending balance at Sep. 30, 2023 $ 48,407 $ 4 433,818 3,905 (389,320)
Beginning balance (in shares) at Mar. 31, 2023   44,403,838      
Beginning balance at Mar. 31, 2023 91,218 $ 4 429,955 3,811 (342,552)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (23,999)       (23,999)
Stock-based compensation 1,798   1,798    
Foreign exchange translation adjustment 171     171  
Shares issued in connection with the Company's Employee stock purchase plan (in shares)   84,533      
Shares issued in connection with the Company's Employee stock purchase plan 96   96    
Ending balance (in shares) at Jun. 30, 2023   44,488,371      
Ending balance at Jun. 30, 2023 69,284 $ 4 431,849 3,982 (366,551)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (22,769)       (22,769)
Stock-based compensation 1,687   1,687    
Foreign exchange translation adjustment (77)     (77)  
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)   107,012      
Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs $ 282   282    
Ending balance (in shares) at Sep. 30, 2023 44,595,383 44,595,383      
Ending balance at Sep. 30, 2023 $ 48,407 $ 4 $ 433,818 $ 3,905 $ (389,320)